ADHD Prescriptions Increase 24.5 Percent After Aussie Coverage
This article was originally published in PharmAsia News
Australian authorities report prescriptions for drugs to treat attention deficit hyperactivity disorder rose by 24.5 percent after the Pharmaceutical Benefits Scheme decided to cover the drugs. Alza's Concerta (methyphenidate hydrochloride), a long-acting stimulate, and Eli Lilly's Strattera (atomoxetine hydrochloride), a non-stimulant, were put on the PBS formulary after the agency decided to cover ADHD beginning last April. The cost of Concerta to patients dropped 80 percent as a result. But the government is about to release the results of a review of the advisability of covering the drugs in the wake of questions raised about the amount of psychiatric drugs prescribed for children. (Click here for more
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.